Posted inBiotechnology
Nektar claims phase 2 alopecia success after excluding patients who ‘should never have been enrolled’
Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia areata, even…







